1999-2023年美国高血压成人心代谢风险因素患病率、治疗与控制趋势
该研究基于NHANES 1999-2023年21,822名高血压成人,评估糖尿病、高脂血症、肥胖、吸烟及高危饮酒的年龄标化患病率及治疗控制趋势。结果显示心代谢风险负担整体增加,并发糖尿病和高脂血症者超过1/5,但三者均控制者仅约1/4且十余年未改善。
要点
- 高血压成人中糖尿病患病率从1999-2000年的17.2%升至2021-2023年的27.8%。
- 高血压合并糖尿病、高脂血症者三种疾病均控制率2021-2023年仅26.3%,十余年无改善。
- 高血压成人中高脂血症患病率仍高达73.1%,肥胖和高危饮酒患病率随时间增加。
核心结论
- 美国高血压成人心代谢风险因素负担整体增加,并发糖尿病和高脂血症者超过1/5。
- 高血压、糖尿病和高脂血症三者均控制的比例仅约四分之一,且十余年未改善。
研究设计与样本
- 基于美国国家健康与营养调查(NHANES)1999至2023年数据,纳入21,822名高血压成人。
- 评估糖尿病、高脂血症、肥胖、吸烟和高危饮酒的年龄标化患病率,以及高血压、糖尿病和高脂血症的年龄标化治疗率和控制率趋势。
主要发现
- 高血压成人中糖尿病患病率从1999-2000年的17.2%(95%CI 14.6%-20.2%)升至2021-2023年的27.8%(95%CI 25.2%-30.7%)。
- 高血压合并糖尿病患者中,两者均治疗的比例升至2009-2010年后平台,2021-2023年为71.6%(95%CI 67.5%-75.4%);两者均控制的比例2021-2023年为31.2%(95%CI 26.5%-36.3%)。
- 高血压成人中高脂血症患病率下降但2021-2023年仍达73.1%(95%CI 70.6%-75.4%);高血压合并高脂血症者两者均治疗和控制的比率仅增至约2007年,2021-2023年分别为50.4%(95%CI 47.2%-53.6%)和32.3%(95%CI 29.5%-35.2%)。
- 高血压成人中并发糖尿病和高脂血症的患病率从1999-2000年的12.5%(95%CI 10.6%-14.7%)几乎翻倍至2021-2023年的21.3%(95%CI 19.0%-23.8%)。
- 高血压、糖尿病和高脂血症三者均治疗的比例增至2007-2008年后平台,2021-2023年为62.1%(95%CI 56.6%-67.2%);三者均控制的比例趋势相似但2021-2023年仍低至26.3%(95%CI 20.8%-32.6%)。
临床怎么用
- 对高血压患者应常规筛查并管理糖尿病、高脂血症、肥胖及高危饮酒等心代谢风险因素。
- 高血压合并糖尿病和/或高脂血症者治疗率虽提高但控制率低,需强化多因素综合管理以改善控制。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hypertension-related deaths in the United States have sharply increased over the past decade. Understanding factors behind this concerning trend is crucial to guide public health strategies. OBJECTIVES: This study sought to examine changes in prevalence, treatment, and control of cardiometabolic risk factors among U.S. adults with hypertension. METHODS: Using National Health and Nutrition Examination Survey, we identified 21,822 adults with hypertension from 1999 to 2023. Trends in age-adjusted prevalence of diabetes, hyperlipidemia, obesity, smoking, and high-risk drinking, as well as in age-adjusted treatment and control rates for hypertension, diabetes, and hyperlipidemia, were assessed. RESULTS: In adults with hypertension, prevalence of diabetes increased from 17.2% (95% CI: 14.6%-20.2%) in 1999-2000 to 27.8% (95% CI: 25.2%-30.7%) in 2021-2023. Among patients with hypertension and diabetes, the proportion receiving treatment for both conditions rose until 2009-2010 but subsequently plateaued (71.6% in 2021-2023; 95% CI: 67.5%-75.4%). A similar trend was observed for the proportion achieving control of both conditions, which remained at 31.2% in 2021-2023 (95% CI: 26.5%-36.3%). Prevalence of hyperlipidemia decreased in adults with hypertension but was still high at 73.1% (95% CI: 70.6%-75.4%) in 2021-2023. Among patients with hypertension and hyperlipidemia, treatment and control rates for both conditions increased only until around 2007; the respective rates were 50.4% (95% CI: 47.2%-53.6%) and 32.3% (95% CI: 29.5%-35.2%) in 2021-2023. Prevalence of concurrent diabetes and hyperlipidemia in adults with hypertension nearly doubled from 12.5% (95% CI: 10.6%-14.7%) in 1999-2000 to 21.3% (95% CI: 19.0%-23.8%) in 2021-2023. Among patients with hypertension, diabetes, and hyperlipidemia, the treatment rate for all 3 conditions increased until 2007-2008 and plateaued afterward (62.1% in 2021-2023; 95% CI: 56.6%-67.2%). The control rate for all 3 conditions followed a similar trend but remained low at 26.3% (95% CI: 20.8%-32.6%) in 2021-2023. Prevalence of obesity and high-risk drinking increased over time, whereas prevalence of smoking held steady. CONCLUSIONS: The burden of cardiometabolic risk factors among U.S. adults with hypertension has increased overall, with concurrent diabetes and hyperlipidemia now affecting more than 1 in 5. Only one-quarter of adults with hypertension, diabetes, and hyperlipidemia have all 3 conditions controlled-a proportion that has not improved in more than a decade.
引用
- Lee HH, Crawford EB, Cho SMJ, et al. Trends in Prevalence, Treatment, and Control of Cardiometabolic Risk Factors Among Adults With Hypertension in the United States, 1999-2023. J Am Coll Cardiol. 2025. PMID: 41295934. doi:10.1016/j.jacc.2025.09.1607
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。